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Abstract
The anti-parasitic benzimidazole flubendazole has been used for many years to treat intestinal 
infections in humans and animals. Previous genotoxicity studies have shown that the compound 
is not a bacterial mutagen and a bone marrow micronucleus test, using a formulation that limited 
systemic absorption, was negative. The purpose of this study is to explore the genotoxicity of 
flubendazole and its main metabolites in in vitro micronucleus studies and to test a new oral 
formulation that improves systemic absorption in an in vivo micronucleus test. The isolated 
metabolites were also screened using the Ames test for bacterial mutagenicity. It was found that 
flubendazole, like other chemically related benzimidazoles used in anti-parasitic therapies, is a 
potent aneugen in vitro. The hydrolysed metabolite of flubendazole is negative in these tests, but 
the reduced metabolite (R- and S-forms) shows both aneugenic and clastogenic activity. However, 
in vitro micronucleus tests of flubendazole in the presence of rat liver S9 gave almost identical 
signals for aneugenicity as they did in the absence of S9, suggesting that any clastogenicity from 
the reduced metabolite is not sufficient to change the overall profile. Like flubendazole itself, both 
metabolites are negative in the Ames test. Analysis of dose–response curves from the in vitro tests, 
using recently developed point of departure approaches, demonstrate that the aneugenic potency 
of flubendazole is very similar to related anti-parasitic benzimidazoles, including albendazole, 
which is used in mass drug administration programmes to combat endemic filarial diseases. 
The in vivo micronucleus test of the new formulation of flubendazole also showed evidence of 
induced aneugenicity. Analysis of the in vivo data allowed a reference dose for aneugenicity to be 
established which can be compared with therapeutic exposures of flubendazole when this has been 
established. Analysis of the plasma from the animals used in the in vivo micronucleus test showed 
that there is increased exposure to flubendazole compared with previously tested formulations, 
as well as significant formation of the non-genotoxic hydrolysed metabolite of flubendazole and 
small levels of the reduced metabolite. In conclusion, this study shows that flubendazole is a potent 
aneugen in vitro with similar potency to chemically related benzimidazoles currently used as anti-
parasitic therapies. The reduced metabolite also has aneugenic properties as well as clastogenic 
properties. Treatment with a new formulation of flubendazole that allows increased systemic 
exposure, compared with previously used formulations, also results in detectable aneugenicity in 
vivo. Based on the lack of carcinogenicity of this class of benzimidazoles and the intended short-
term dosing, it is unlikely that flubendazole treatment will pose a carcinogenic risk to patients.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), 
which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact 
journals.permissions@oup.com
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Introduction
Filarial worm parasitic diseases are highly prevalent in the poorest 
regions of the world and are transmitted by specific insect vectors, 
the river blackfly for onchocerciasis and the mosquito for lymphatic 
filariasis (LF). Approximately 1.3 billion people are at risk and 120 
million are infected with LF caused by Wuchereria bancrofti and 
Brugia spp. (1). For onchocerciasis, at least 25 million people are 
infected with Onchocerca volvulus and 130 million people are at 
risk of infection (2,3). Many millions are also at high risk of infec-
tion with a third form of filariasis, loiasis, caused by the Loa loa 
parasite (4).
Filarial diseases are treated in mass drug administration (MDA) 
programmes, currently with the benzimidazole, albendazole in com-
bination with either ivermectin or diethylcarbamazine. The aims of 
the MDA programmes are to reduce the immature microfilarial load 
in patients and to halt disease transmission. As reproductively active 
adult macrofilariae can live for 12 years, MDA treatments are pro-
longed and so far have been running for more than 12 years in some 
territories (5).
Over 14 million people are co-infected with Onchocerca and 
L. loa and are treated using ivermectin alone or in combination with 
albendazole, which can result in undesirable side-effects of encepha-
lopathy and brain dysfunction, potentially leading to coma and 
death (4). Thus, there is an urgent need for a new, safe and effective 
treatment.
Flubendazole, an antihelmintic benzimidazole carbamate, is 
effective for treating gastrointestinal (GI) parasites in humans 
and animals (6) and is a highly active agent against macrofilariae. 
However, flubendazole, as currently formulated for this purpose, has 
poor systemic availability when given orally (6). In order to improve 
systemic bioavailability it has been reformulated as an amorphous 
solid dispersion (ASD) oral formulation. If clinical development of 
such a new formulation is successful, flubendazole would be valu-
able for case management in areas of high risk of co-infection. Since 
flubendazole has macrofilaricidal activity, it is hoped that the dosing 
period could be significantly reduced to a few days (7).
Due to its poor bioavailability and solubility, the original oral for-
mulation for GI infections induces limited systemic or GI toxicities. 
In addition, bone marrow micronucleus tests to detect chromosome 
damage are negative, as are tests to measure the induction of domi-
nant lethal mutations in treated mice. Flubendazole is negative in the 
Ames bacterial mutation test and also tests to measure the induction 
of DNA repair in Bacillus subtilis (8). Mutation tests in the yeast 
Saccharomyces cerevisiae and the fruit fly Drosophila melanogaster 
are also negative (8). Many benzimidazoles, including flubendazole, 
bind to the same site on the tubulin protein as colchicine but distinct 
from Vinca alkaloids such as vinblastine, inhibiting the polymerisa-
tion of tubulin and thus disrupting the mitotic spindle (9). Spindle 
poisons all have the potential to induce polyploidy (multiple sets of 
the chromosome complement) and aneugenicity (loss and gain of 
small numbers of chromosomes). Flubendazole has been shown to 
induce polyploidy in CHL cells and morphological transformation 
in C3H/10T1/2 Cl 8 mouse embryo fibroblasts (9).
As the new oral ASD formulation allows improved systemic 
absorption, it was necessary to re-evaluate the toxicity of flubenda-
zole including potential genotoxicity.
Non-DNA reactive genotoxic substances are widely accepted as 
having threshold dose responses (10–15). Aneugens were the first sub-
stances within this category, to have clear non-linear dose responses 
accepted with a clear mode of action (MOA) (10,11). In fact, benzi-
midazoles were included in this first set of studies that initiated the 
paradigm shift from the default that all genotoxic substances had a 
linear dose response. The aneugenic MOA is either mitotic spindle 
depolymerisation or inhibition of polymerisation, and both mecha-
nisms lead to chromosome loss and non-disjunction. Chromosome 
loss is readily quantified using the micronucleus assay, and numerous 
aneugens have well characterised threshold responses for this end-
point in vitro and in vivo (10–18). A recent review presents clearly 
defined no observed genotoxic effect levels (NOGELs) in vitro and 
in vivo, for the aneugenic substances colchicine, carbendazim, noco-
dazole, mebendazole, benomyl, nitrobenzene, benzonitrile, paclitaxel, 
bisphenol-A, rotenone, vincristine and vinblastine (19).
The UK Department of Health’s Committee on Mutagenicity 
(COM) have stated that ‘it is reasonable to assume that aneuploidy 
inducing chemicals (particularly those that function by interfering 
with the spindle apparatus of cell division) may have a threshold 
mode of action’ (20). In a more recent report the COM advised that 
‘there is sound scientific basis to assume that benzimidazoles have 
a threshold of action in both somatic and germ cells’ (11). ‘It was 
not considered essential for a benzimidazole to have been studied 
in vivo for it to be included in the common mechanism group, since 
the available data indicated that in vitro aneugenicity is a good pre-
dictor of in vivo aneugenicity for the benzimidazoles’. Mebendazole 
has also been well characterised as having a NOGEL and threshold 
dose response for chromosome loss (12–14,18). It is therefore key 
to note that benzimidazoles are used as an exemplar case to show 
that similar acting aneugens can be assessed together for hazard and 
risk assessment (12–22). This, together with the fact that they are 
accepted as having threshold dose responses for aneuploidy, means it 
is likely that the benzimidazole flubendazole, will have similar points 
of departure (PoD) in the form of NOGEL, threshold (Td) and/or 
benchmark dose (BMD) as previously studied compounds of this 
class (22).
The purpose of this study is to investigate the aneugenicity of 
flubendazole and its significant metabolites, the hydrolysed and 
reduced (R- and S-derivatives) using in vitro and in vivo micronu-
cleus tests. Micronucleus tests are established assays to measure both 
chromosome structural damage (clastogenicity) and chromosome 
number changes (aneugenicity) when used in conjunction with cen-
tromeric staining. The in vivo test was carried out to determine if the 
new oral ASD formulation, with improved bioavailability of fluben-
dazole, increases systemic levels sufficiently to induce aneugenicity. 
This is in contrast to the previous oral GI formulation, which gave 
a negative response in the bone marrow micronucleus test. In addi-
tion, the consequence of in vivo metabolism could also be evalu-
ated. Recently developed methods to explore PoD of response were 
used to help establish reference doses from the in vivo micronucleus 
test dose–response data and to allow in vitro data comparisons with 
established aneugens of the same chemical class, to aid understand-
ing of the hazards posed by flubendazole treatment of patients. Thus, 
this work aimed to establish the aneugenicty potency of flubenda-
zole and its metabolites in vitro and in vivo for the first time and to 
provide a valuable example of how genetic toxicity dose response 
data from aneugens can be used for human health risk assessment 
purposes.
Materials and methods
Test materials
The chemical structure of flubendazole and its two major metab-
olites, the reduced form and the hydrolysed form, are shown in 
Figure 1. The chemical structures of mebendazole, albendazole and 
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albendazole sulfoxide are also presented. Flubendazole batch number 
EPL-BS1065 Batch 3, purity 99.2% (Epichem, Murdoch University 
Campus, Murdoch, Australia) was used for the initial in vitro experi-
ments. Flubendazole Amorphous Solid Dispersion batch number 
10035642-0060, purity 99.2% (Abbot Laboratories, Abbott Park, 
IL, USA) was used for the in vivo experiment. Flubendazole (batch 
number SZBB157XV, purity 99.2%, supplied by Sigma–Aldrich) 
was used as a comparator in the in vitro experiments with the 
metabolites. For the in vivo experiment with flubendazole, an ASD 
formulation (Flubendazole: vitamin E TPGS: Copovidone (10:5:85) 
%w/w) was used. For this study doses are expressed in terms of mg 
flubendazole/kg following a correction factor for purity of ×11.35 
(88.1 mg flubendazole/g solid dispersion). Formulations were freshly 
prepared in purified water prior to each dosing occasion. To ensure 
homogeneity, dose bottles were stirred continuously (on a magnetic 
stirrer) immediately before and throughout dosing. Samples were 
assessed for achieved concentration and homogeneity (Day 1 prepa-
ration) and achieved concentration (Day 2 preparation).
For the in vitro micronucleus tests, hydrolysed flubendazole 
(JNJ-114699) batch number EPL BS1151 was used. Its purity was 
98.4%. S-reduced flubendazole (JNJ-60281156), batch number 
42417796 was used. Purity was >95%. R-reduced flubendazole (JNJ-
60774643), batch number 42414540 was used. Purity was >95%. 
These compounds were kindly supplied by Janssen Pharmaceutica 
N.V, Beerse, Belgium (a Johnson and Johnson company). The metab-
olites were dissolved in anhydrous, analytical grade DMSO.
For the Ames tests, hydrolysed flubendazole, EPL-BS 1151, batch 
number 1 and reduced flubendazole (racemate), batch number 1, 
both manufactured by Epichem Pty Ltd were used. Both had a purity 
of 98.4%.
For in vitro studies flubendazole and its metabolites, were dis-
solved in anhydrous analytical grade DMSO.
Albendazole (Sigma–Aldrich, batch number SLBD9170V, purity 
99%) and albendazole sulfoxide (Sigma-Aldrich, batch number 
SZBD049XV, purity 99.9%) were used as comparators in the in 
vitro experiments with the metabolites. These compounds were dis-
solved in anhydrous, analytical grade DMSO.
The positive control compounds mitomycin C and vinblastine 
sulfate were obtained from Sigma–Aldrich Chemical Co, Poole, 
Dorset, UK. Cyclophosphamide was obtained from Arcos Organics, 
Loughborough, Leicestershire, UK.
Test methods
In vitro micronucleus test
Blood was taken from two healthy non-smoking, healthy male vol-
unteers, who were not taking any medication. Whole blood cultures 
were prepared by pipetting 0.8 ml of pooled heparinised blood into 
hydroxyethylpiperazine-N’-2-ethanesulfonic acid-buffered RPMI 
media containing 10% (v/v) heat-inactivated foetal calf serum plus 
penicillin and streptomycin. The mitogen phytohaemagglutinin 
was included in the media at a concentration of approximately 2% 
(v/v) and the cultures (9.4 ml) incubated at 37 C for 48 h prior to 
treatment.
Test chemicals were dissolved in reagent grade DMSO. Stock 
solutions of test chemicals were prepared at 100× the required final 
concentrations approximately 2–3 h prior to treatment and diluted 
100-fold directly in the blood cultures with mixing (0.1 ml additions).
Blood cultures were treated with test substance or controls for 3 
or 24 h. Solutions of 150 mM KCl or rat liver S9-mix (0.5 ml) were 
added as appropriate (final culture volume was 10 ml). Cultures 
were incubated at 37°C.
Following short (3 h) or extended (24 h) treatments the com-
pound was removed (via centrifugation), washed in sterile saline 
and resuspended in pre-warmed media containing foetal calf 
serum and streptomycin/penicillin. Cytochalasin B was added to 
give a final concentration of 6 μg/ml and the cell cultures incu-
bated for an additional 21 or 24 h (3 + 21 h or 24 + 24 h treat-
ments). Total time from initiation of blood culture to cell harvest 
was either 72 or 96 h.
Initial flubendazole experiments were performed using short 
(3 h), plus +/−S9 and 24 h treatment with 24 h recovery −S9. For the 
studies with flubendazole metabolites plus comparator compounds, 
24 h treatment with 24 h recovery alone was used.
Following treatment, at the time of cell harvest, cultures were 
then centrifuged, the supernatant discarded and the pellets resus-
pended in 4 ml of 0.075 M KCl (hypotonic solution) to swell the 
cells, for 4 min. The cells were then then fixed in ice-cold methanol/
glacial acetic acid (7:1 v/v). This procedure was repeated as deemed 
necessary. Cells were pelleted after fixation and resuspended in a 
small amount of fixative. Drops of this cell suspension were used 
to prepare several slides per culture. The slides were air-dried and 
stained with 125 µg/ml acridine orange. Slides were protected from 
light before scoring.
Figure 1. Chemical structures of flubendazole, its metabolites and related benzimidazole anti-parasitic compounds.
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Where possible, 1000 binucleate cells from each culture (2000 
per concentration of test substance and the positive controls and 
4000 per concentration for vehicle controls) were analysed for 
micronuclei. After completion of scoring and decoding of slides, the 
numbers of binucleate cells with micronuclei (MNBN cells) in each 
culture were obtained.
The proportions of MNBN cells in each replicate were used to 
establish acceptable heterogeneity between replicates by means of a 
binomial dispersion test.
For each study acceptance criteria were met as follows:
1. The binomial dispersion test demonstrated acceptable heteroge-
neity (in terms of MNBN cell frequency) between replicate cul-
tures, particularly where no positive responses were seen.
2. The frequency of MNBN cells in vehicle controls fell within the 
laboratory’s historical vehicle control (normal) ranges.
3. The positive control chemicals induced statistically significant 
increases in the proportion of cells with micronuclei. Both replicate 
cultures at the positive control concentration analysed under each 
treatment condition demonstrated MNBN cell frequencies that 
clearly exceeded the laboratory’s historical vehicle control ranges.
4. A minimum of 50% of cells had gone through at least one cell 
division (as measured by binucleate + multinucleate cell counts) 
in negative control cultures at the time of harvest.
The proportion of MNBN cells for each treatment condition was 
compared with the proportion in negative controls by using Fisher’s 
exact test. Probability values of P ≤ 0.05 were accepted as significant. 
Additionally, the number of micronuclei per binucleate cell were 
obtained and recorded.
The replication index (RI), which indicates the relative number of 
nuclei compared with controls was used as a measure of cytotoxicity 
and determined using the formulae below (23):
RI =
Number binucleate cells + 2 (Number multinucleate cells)
Total number of cells in treated cultures
Relative RI (expressed in terms of percentage) for each treated 
culture was calculated as follows:
Relative RI (%) =
RI of treated cultures  
× 100
RI of vehicle controls
Cytotoxicity (%) is expressed as (100 − Relative RI).
Mechanism of action studies (FISH analysis)
In order to determine if the micronuclei observed were generated 
primarily as a result of clastogenicity or aneugenicity, fluorescence in 
situ hybridization (FISH) with pan-centromeric human DNA probes 
(PlaninumBright™550 (Ex/Em 550/580), Filter: TRITC (pan-cen-
tromere probe and chromosome specific centromere probes) was used 
to highlight if micronuclei contained centromeres or not. Fluorophores 
and filters for probes were obtained from Leica Microsytems, Ltd, UK.
Those micronuclei containing a centromere were deemed to con-
tain a whole chromosome as a result of spindle malfunction (aneu-
genicity), whereas those that did not contain a centromere were 
deemed to result from chromosome breakage (clastogenicity).
Freshly prepared slides from stored cell pellets were processed 
from cultures exposed to flubendazole concentrations of 7.5 and 
9.0 μg/ml (3 + 21 h −S-9); at 16 and 25 μg/ml (3 + 21 h +S-9) and 3.0 
and 5.0 μg/ml (24 + 24 h −S-9).
Prior to hybridisation, the sample slides were pre-treated in 2 × 
SSC/0.5% IGEPAL®CA630 (Sigma–Aldrich, UK), a non-ionic, non-
denaturing detergent, octylphenoxypolyethoxyethanol, pH 7.0 ± 0.1, 
at approximately 37°C for 15 min. The slides were dehydrated by 
placing them through a series of ethanol washes (70%, 85% and 
100% ethanol) for 1 min each prior to drying at room temperature 
(15–30°C). The samples and FISH probe (pan-centromere) were co-
denatured using the StatSpin®ThermoBriteTM Denaturation and 
Hybridisation System, as follows: 20 µl of FISH probe (per slide) was 
added with the application of a glass coverslip and sealed by rub-
ber cement. The sample and FISH probe were denatured at 75 ± 1°C 
for 5 min using the StatSpin®ThermoBriteTM. The slides were 
hybridised overnight in a humidified chamber at 37 ± 1°C using the 
StatSpi®ThermoBriteTM, containing humidity strips saturated with 
distilled water. Following overnight hybridisation, the rubber cement 
was removed and the slides washed with 2 × SSC/0.1% igepal for 
2 min at room temperature. The coverslips were carefully removed 
and the slides washed in 0.4 × SSC/0.3% igepal for 2 min at 72 ± 1°C 
followed by 2 × SSC/0.1% igepal for 1 min at room temperature. The 
slides were dehydrated by placing them through a series of ethanol 
washes (70%, 85% and 100% ethanol) for 1 min each. Slides were 
allowed to air dry prior to mounting in DAPI antifade and stored at 
−20°C until analysis.
Slide analysis was conducted using fluorescence microscopy using 
appropriate filters. Slides from the selected treatments and controls 
were coded (analysis was conducted ‘blind’). Where possible, one 
hundred MNBN cells per concentration were analysed. Micronuclei 
were classified as centromere-positive if one or more fluorescent sig-
nals were present and centromere-negative if no fluorescent signals 
were observed. After completion of scoring and decoding of slides, 
the proportions of centromere positive and centromere negative 
micronuclei (per concentration) were obtained and tabulated.
Bone marrow micronucleus test
Groups of seven young, out-bred female Han Wistar rats [Cr1 
WI(Han)], were obtained from Charles River (UK) Ltd, UK. 
Animals were housed in groups of no more than seven per cage in 
wire topped, solid bottomed cages. Animals were housed in rooms 
air-conditioned to provide 15–20 air changes/hour. Temperature 
and humidity ranges were 20–24°C and 45–65%, respectively. 
Fluorescent lighting was controlled automatically to give a cycle 
of 12 h light (0600 to 1800) and 12 h dark. Animals were acclima-
tised for 7 days prior to dosing. Throughout the study, animals had 
access ad libitum to SQC Rat and Mouse Maintenance Diet No 1, 
Expanded (Special Diets Services Ltd. Witham). Mains water was 
provided ad libitum via water bottles. Bedding used was European 
softwood bedding (Datesand Ltd, Manchester, UK). Aspen chew 
block and rodent retreats were provided to enrich the environment 
and welfare of the animals. The rats were approximately 9 weeks old 
with a weight range of 169–216 g on the first day of dosing.
Animals were given flubendazole formulations, or solutions of 
the controls, by oral gavage. Doses were given at 0 and 24 h and 
the animals killed 24 h after the second dose. The doses of fluben-
dazole selected were 65, 130 and 400 mg/kg/day based on previ-
ous dose range finding studies. The top dose was limited by the 
viscosity of the formulation. Female animals were chosen for the 
study based on previous toxicology studies showing that slightly 
higher exposures could be achieved in this gender compared to 
male animals. Satellite animals were included to allow estimation 
of the exposure of flubendazole and its reduced and hydrolysed 
major metabolites.
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Bone marrow smears were prepared from washed and filtered 
femoral bone marrow samples obtained from the animals on test. 
After fixing and staining with acridine orange, slides were scored 
using fluorescence microscopy. Two thousand polychromatic eryth-
rocytes (PCE) were scored for the presence of micronuclei and 
the relative proportion of PCE were determined among a total of 
500 erythrocytes [PCE and normochromatic erythrocytes (NCE)] 
scored.
The percentage of PCE’s for each animal and the mean percent-
age of PCE’s of each group were used to estimate if any bone mar-
row toxicity was induced in the treated animals compared with the 
vehicle controls. For each group, inter-individual variation in the 
numbers of micronucleated PCE’s was estimated using a heterogene-
ity chi-square calculation. The numbers of micronucleated PCE’s in 
each treatment group were compared with those of the vehicle con-
trol using a 2 × 2 contingency table to determine chi-square and thus 
allow statistically significant changes to be identified. A linear trend 
test was used to evaluate the dose–response relationship observed.
Exposure assessment
Groups of female satellite animals were dosed with vehicle or fluben-
dazole (high dose). Animals were dosed by the same route, dose level 
and at the same dosing frequency as that described for the micronu-
cleus experiment animals. Plasma was isolated from these animals at 
9 and 24 h and used to assess systemic exposure to flubendazole and 
its two significant metabolites. Rat plasma concentrations of fluben-
dazole, reduced flubendazole and hydrolysed flubendazole were 
determined using a LC-MS-MS method following plasma protein 
precipitation (see supplementary Method for full details).
Ames tests
Salmonella typhimurium strains TA98, TA100, TA1537, TA1535 
and Escherichia coli strain WP2 uvrA (Molecular Toxicology, Inc.) 
were used in this study. The preincubation method (24) was used. 
Histidine auxotrophs (strains TA98, TA100, TA1535 and TA1537) 
of S. typhimurium and the tryptophan auxotroph E. coli WP2 uvrA 
were thawed from frozen permanent cultures and grown overnight 
in Oxoid broth No. 2. The test item was diluted in the chosen solvent 
at concentrations determined in a range-finding test. The bacteria 
(approximately 1–3 × 108in 100 μl) were combined with 50 μl of 
either the test item, the solvent control, or 50 μl of positive control 
and 500 μl of the phosphate buffer (pH 7.4) and preincubated at 
37 ± 1°C for approximately 30 min. After the preincubation period, 
the content of each tube was combined with 2 ml of top agar (45°C) 
containing 50 μM of histidine and tryptophan to give a total vol-
ume of 2650 μl. The mixture was then poured onto a 90-mm plate 
(each well resulting from an independent treatment tube) contain-
ing histidine/tryptophan-deficient base agar and was incubated at 
37 ± 1°C for 3 days. After incubation the plates were examined for 
the presence of a precipitate and for signs of toxicity as indicated by 
a diminished or absent background lawn or reduced colony numbers 
as compared with the solvent control. The colonies were counted 
using an automatic colony counter (Sorcerer–Perceptive).
Determination of PoD metrics
The BMD approach was used as a potential improvement on the 
no observed effect level (NOEL) approach (25,26). BMD has 
been used as a PoD when carrying out hazard and risk assess-
ment using both cancer and non-cancer endpoints, but has only 
recently been used for the purpose of genetic toxicology data (26). 
The International Life Science Institute (ILSI) Genetic Toxicology 
Technical Committee (GTTC), previously the IVGT, tested this 
methodology and confirmed its suitability. Another great benefit 
is the extensive work that the National Institute for Public Health 
and the Environment (RIVM) did with support from the Food and 
Drug Administration (FDA). They carried out potency correlations 
for numerous genotoxic carcinogens using BMD for both genetic 
toxicology and carcinogenicity endpoints, and found a positive 
correlation (26–29). NOGEL and Td metrics are not suitable for 
carrying out these potency ranking correlations due to data limita-
tions as well as limitations in the statistical approaches themselves. 
Both potency estimates are highly sensitive to experimental design 
differences, and the NOGEL is also not very accurate and does 
not provide a measure of uncertainty (29). Therefore, BMD was 
considered the best choice for carrying out the potency rankings 
for these benzimidazoles, which then allowed the grouping of these 
substances, which is the advised approach from the UK COM.
(20) Therefore, all in vitro dose responses were assessed using the 
PROAST software, and the BMD PoD metrics for each compound 
were defined (29–31).
PROAST version 50.8 (under development) was used to carry out 
covariate BMD analysis for potency ranking (http://www.proast.nl) 
(29). The four-parameter ‘full’ exponential model is recommended 
for the analysis of these continuous micronucleus data, when using 
the compound as a covariate (25,27,28). During this combined anal-
ysis, the shape parameters for maximum response (parameter c) and 
log-steepness (d) were assumed equal, while background response 
(a), potency (b) and the additional parameter representing within 
group variation (var) were covariate dependent (28). Individual fits 
at the covariate level for all datasets are presented in supplementary 
Figures 1 and 2.
A BMDL10 refers to the estimate of lower 95% confidence inter-
val of a dose that produces a 10% increase over the back-ground 
level for continuous endpoints such as frequencies of micronuclei 
(BMD10), and 10% extra risk for quantal endpoints (25). BMDU10 
refers to the upper estimate of this same confidence interval. Ten 
percent is an arbitrary but common choice (30–33), and changing 
this to a different benchmark response [BMR, or critical effect size 
(CES)] has recently been shown to have no effect on the potency 
rankings (27). In these in vitro potency-ranking plots, the width of 
the confidence interval between BMDL10–BMDU10 represents the 
precision to which the BMD10 can be defined. Ranking these by 
midpoint was chosen as the most suitable way to compare potency 
across the different chemicals (covariate). The (BMR) of one stand-
ard deviation above the spontaneous (control) value (BMD1SD) 
was used for the in vivo MN dose response data, which is also 
a recommended approach from the GTTC and International 
Workgroup on Genotoxicity Testing (30,31). This BMR is recog-
nised to be equivalent to 10% excess risk for individuals below 
and above the 2nd and 98th percentiles, respectively for micro-
nucleus induction over the negative control frequency in this case 
(34). Model selection was primarily based upon the P-value for 
goodness-of-fit to the data and the Akaike’s Information Criterion 
(AIC). For this study, the best fitting model was selected from 
among the suite of continuous models, using EPA’s Benchmark 
Dose Software (i.e. BMDS v2.5). Response data were transformed 
in order to achieve normally distributed data with homogeneous 
variance prior to analysis with the BMDS software (32). This same 
approach to transformation was taken when deriving the fluben-
dazole NOGEL using the one-sided Dunnett’s test (P < 0.05) in the 
‘drsmooth’ package of R (32,33,35,36).
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Results
In vitro lymphocyte micronucleus tests of 
flubendazole
The results of the in vitro micronucleus tests of flubendazole are 
shown in Tables 1 (short exposure with and without rat liver S9) 
and 2 (long exposure without rat liver S9). These show that fluben-
dazole is a potent aneugen in vitro. After short exposure, statisti-
cally significant increases in micronucleated binucleate lymphocytes 
are seen at doses of flubendazole of 5.0 µg/ml (−S9) and 14.0 µg/
ml (+S9). These differences reflect the lower cytotoxicity of fluben-
dazole exposure +S9, which suggests that flubendazole metabolites 
formed by the rat liver S9 may be less toxic than the parent molecule, 
as confirmed by the tests on the isolated metabolites shown below. 
After longer-term exposure, cytotoxicity is increased, as does the 
aneugenic action of flubendazole. In the first experiment, statistically 
significant increases in micronuclei were evident at the lowest tested 
concentration of 0.5 µg/ml. Thus, a second experiment was carried 
out covering a lower concentration range. In this second experiment 
the lowest dose where a statistically significant increase in micronu-
clei was observed was 0.25 µg/ml.
To determine if the micronuclei observed were due to a clasto-
genic or a aneugenic MOA, a mechanistic study was carried out using 
centromeric stains (FISH technique) to determine if the micronuclei 
contained a centromere, where it is assumed that such micronuclei 
are formed from whole chromosomes as a result of spindle malfunc-
tion or lack a centromere and are thus likely to be formed from 
chromosome fragments. The results are shown in Table  3. As the 
micronuclei predominantly stain positively for centromeres, fluben-
dazole acts as an aneugen. This was also the case for the micronuclei 
induced by flubendazole in the presence of S9, indicating that fluben-
dazole metabolism in vitro does not result in the formation of detect-
ably clastogenic metabolites under the conditions used.
The analysis of thresholds (PoD metrics) for the induction of micro-
nuclei by albendazole, benomyl, carbendazim, flubendazole, mebenda-
zole, oxibendazole and albendazole oxide in CHO-K1 cells (19) are 
shown in Table 4 and Figure 2. These show that the PoDs for fluben-
dazole, oxibendaolze, mebendazole and albendazole are very similar, 
and more specifically were equipotent as observed by the overlapping 
BMDL10–BMDU10 from the covariate BMD analysis. Albendazole 
oxide was also clearly shown to be less potent than the parent com-
pound due to its lack of overlap in BMD with the other compounds.
In vitro micronucleus test of flubendazole 
metabolites
In vitro micronucleus tests were carried out with the hydro-
lysed metabolite and the R-reduced and S-reduced metabolites of 
Table 1. In vitro micronucleus test results in human lymphocytes 
following treatment with flubendazole after short (3 h) exposure
Treatment Flubendazole 
(µg/ml)
Cytotoxicity (%) Mean MNBN cell 
frequency (%)
3 + 21 h –S9 0.0 (Vehicle) 0.0 0.23
2.0 0.0 0.05
5.0 7.0 0.55*
6.0 0.0 0.85*
7.5 8.0 1.65*
9.0 26.0 6.55*
MMC (0.80) – 8.70*
3 + 21 h +S9 0.0 (Vehicle) 0.0 0.25
10.0 0.0 0.25
12.0 0.0 0.20
14.0 14.0 0.65*
16.0 4.0 0.90*
19.0 7.0 0.55*
25.0 12.0 2.88*
CYC (12.5) – 1.40*
Historical control range for the testing laboratory was 0.1–0.95 and 0–1.1 
for –S9 and +S9, respectively. MMC, mitomycin C; CYC, cyclophosphamide.
*Statistically significant.
Table 2. In vitro micronucleus test results in human lymphocytes fol-
lowing treatment with flubendazole after long (24 h +24 h) treatment
Experiment Flubendazole  
(µg/ml)
Cytotoxicity (%) Mean MNBN cell 
frequency (%)
I 0.0 (Vehicle) 0.0 0.30
0.5 4.0 1.75*
1.0 0.0 3.38*
3.0 0.0 5.15*
5.0 28.0 4.74*
6.5 43.0 10.10*
VIN (0.12) – 16.99*
II 0 (Vehicle) 0.0 0.28
0.050 0.0 0.10
0.075 0.0 0.30
0.100 0.0 0.55
0.250 0.0 1.15*
0.500 0.0 3.15*
1.00 16.0 4.25*
VIN (0.08) – 4.25*
VIN, vinblastine sulphate.
*Statistically significant (P > 0.05).
Table 3. Mechanistic study in vitro, to show the percentage of micronuclei with and without centromeres, to determine aneugenicity or 
clastogenicity, respectively
Compound Concentration 
μg/ml
Fold increases in MN over 
concurrent vehicle control
% micronuclei with a 
centromere
% micronuclei without a 
centromere
Total MN cells scored
Flubendazole (3 h + 21 h, −S9) 7.5 7.2 80 20 100
9.0 28.5 88 12 100
Flubendazole (3 h + 21 h, +S9) 16 3.6 83 17 100
25 11.5 86 14 100
Cyclophosphamide 12.5 5.6 16 84 100
Vinblastine 0.12 56.6 73 11 84
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flubendazole, using flubendazole, albendazole and albendazole sul-
foxide as comparators. The most sensitive exposure condition deter-
mined for flubendazole of 24 h (plus 24 h recovery) was used. The 
results are shown in Tables 5–7 (metabolites) and 8 (comparator com-
pounds). It can be seen that the hydrolysed metabolite is inactive at 
test concentrations up to 100 µg per ml (54% cytotoxicity). However, 
there was a clear dose related induction of micronuclei from both the 
R- and S-reduced metabolites. For the R-reduced metabolite a sig-
nificant increase in micronuclei was seen at the lowest dose of 1.1 µg 
per ml, whereas with the S-reduced metabolite, the response with the 
lowest dose, 1.5 µg per ml, was similar to that of the vehicle control, 
whereas increases in micronucleated cells were seen at all the higher 
doses for both enantiomers. Flubendazole, albendazole and albenda-
zole sulfoxide all gave the expected increases in micronuclei with the 
lowest non-significant doses, 0.1 µg per ml (flubendazole) 0.04 µg per 
ml (albendazole) and 3.0 µg per ml (albendazole sulfoxide).
Table  4. Threshold dose (Td) PoD metrics defined for CHO-K1 
cells treated with benzimidazoles with CBMN endpoint, with back-
ground MNBN% defined along with Td and lower confidence Td–L–
CI as calculated in the article by Ermler et al. (19)
Compound Td  
(µg/ml)
Td–L–CI 
(µg/ml)
BMD10  
(µg/ml)
BMDL10 
(µg/ml)
Albendazole 0.005 0.003 0.037 0.027
Benomyl 0.659 0.520 0.450 0.348
Carbendazim 0.346 0.268 0.310 0.235
Flubendazole 0.028 0.025 0.019 0.013
Mebendazole 0.032 0.027 0.024 0.018
Oxibendazole 0.032 0.032 0.015 0.010
Albendazole oxide 1.708 1.474 1.100 0.861
BMD covariate analysis in PROAST version 50.8, used to define these 
BMD10 metrics is presented in Figure 2.
Figure 2. BMD10 analysis of in vitro MN dose responses in Chinese hamster ovary (CHO-K1) cells following exposure to the benzimidazoles, oxibendazole (grey), 
flubendazole (light blue), mebendazole (pink), albendazole (black), carbendazim (dark blue), benomyl (green) and albendazole oxide (red) (19). The figure was 
modified from the article (37). The top figure shows that the four parameter (m5-bv) exponential model provided a suitable fit to each dose response using the 
compound as covariate for BMD analysis. The dotted lines show the BMD10 derivations for each dose response, and these correspond to the mid-point for each 
line plotted in the bottom figure. These lines in the bottom graph span the BMDL10 to the BMDU10 derived from the top figure using PROAST v50.8. Flubendazole, 
oxibendazole and mebendazole grouped together along with albendazole. Benomyl and carbendazim also grouped together with albendazole oxide being a lot 
less potent and forming no groupings. The individual plots are located in supplementary Figure 2.
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BMD covariate analysis was used again to rank and group fluben-
dazole, albendazole and their metabolites together based on the potency 
measure of overlapping BMDL10–BMDU10. Figure 2 shows equipotency 
and clear grouping of flubendazole, oxibendazole, mebendazole and 
albendazole, whereas Figure 3 shows the potency of the S- and R- enan-
tiomers of the reduced flubendazole metabolite along with albendazole 
sulfoxide formed a separate grouping due to their lower potencies. This 
is in line with the recent analysis of tests of most of these substances 
using the MN endpoint in CHO-K1 cells by Ermler et al. (19) (Figure 2).
As for flubendazole above, centromeric stains were used to 
determine if the micronuclei induced by the two reduced metabolite 
enantiomers contained a centromere and thus to determine if the 
micronuclei were formed due to aneugenicity and/or clastogenicity. 
The data are shown in Table 9. Surprisingly, it was found that both 
compounds showed evidence of both clastogenic and aneugenic 
activity, in that both centromere positive and centromere negative 
micronuclei were observed. For the R-enantiomer, approximately 
equal numbers of centromere positive and centromere negative 
micronuclei were detected, whereas for the S-enantiomer, approxi-
mately 65% of the micronuclei did not contain a centromere. The 
comparator compounds, including flubendazole, as expected, all 
showed a predominance of C+ staining micronuclei confirming 
aneugenicity, whereas the clastogen mitomycin C showed predomi-
nantly C− stained micronuclei confirming clastogenicity. Analysis 
of the micronuclei induced by flubendazole in the presence of S9 
using centromeric staining gave almost identical levels of C+ and 
C− containing micronuclei as tests in the absence of S9, that is pre-
dominantly C+ micronuclei indicative of aneugenicity. Thus, if the 
reduced metabolite is formed by the action of S9 it does not induce 
sufficient micronuclei due to clastogenicity to make a difference 
under the conditions of the assay.
Ames tests of the flubendazole metabolites
The results of the Ames tests of hydrolysed flubendazole and reduced 
flubendazole (racemate) can be accessed online (supplementary 
Tables 1a and 1b). Neither compound showed any dose related 
increase in revertants in any test strain used.
In vivo bone marrow micronucleus test
A previous toxicity test of the new formulation of flubendazole provided 
data on plasma exposures of the parent compound (Table  10). This 
showed that exposure to flubendazole is sub-linear with small increases 
in exposure between 65 and 400 mg/kg. The results of the rat bone mar-
row micronucleus test using similar doses are shown in Table 11. It can 
be seen that contrary to previously published negative bone marrow 
micronucleus tests of flubendazole with alternative formulations (8), the 
new formulation of flubendazole induces micronuclei at all tested doses. 
In addition, there was a decrease in the PCE/NCE ratio with increas-
ing dose, indicative of bone marrow toxicity as might be expected from 
exposure to an aneugen and the resulting cell cycle delay. The BMD anal-
ysis shown in Figure 4, using the BMDS software, estimates the likely 
PoD from these data. Thus for the administered dose, the BMD1SD is 
calculated as 18.97 mg/kg and the BMDL1SD as 14.65 mg/kg.
Table  12 shows exposure to flubendazole and its two major 
metabolites 9 h after administration of the highest dose of 400 mg/
kg. This shows that animals have detectable exposure to all three 
compounds with the non-genotoxic hydrolysed metabolite showing 
by far the greatest exposure compared with the other two molecules.
Discussion
This article shows that the benzimidazole flubendazole is a potent 
aneugen in vitro in human lymphocytes. Flubendazole is extensively 
metabolised in vivo to a hydrolysed form and small amounts of a 
reduced form (R- and S-enantiomers). In vitro micronucleus tests of 
these metabolites show that the hydrolysed form (by far the most 
prevalent metabolite) is not genotoxic, but both the S- and R-form 
of the reduced metabolite, when tested in isolation, showed both 
Table  6. In vitro micronucleus test of R-reduced flubendazole 
(combined data from two experiments)
Concentration  
(µg/ml)
Cytotoxicity (%) Frequency of microncucleated 
binucleate cells (%)*
0.0 0.0 0.30a/0.65
1.1a 10.0 0.85
3.2a 18.0 2.25
8.8a 3.0 2.75
10.0 0.0 5.05
20.0 0.0 4.50
24.5a 3.0 2.75
35.0 17.0 3.95
40.0 22.0 3.75
45.0 15.0 2.90
aData from Experiment 1, all other data is from Experiment 2.
*All treated groups gave increases in micronucleated binucleate cells that 
were statistically significant relative to the vehicle control P < 0.05.
Table 7. In vitro micronucleus test of S-reduced flubendazole (com-
bined data from two experiments)
Concentration 
(µg/ml)
Cytotoxicity (%) Frequency of micronucleated 
binucleate cells (%)
0.0a 0.0 0.6a/0.6
1.5a 0.0 0.65
4.2a 3.0 1.25*
11.7a 12.0 3.90*
20.0 11.0 4.00*
32.4a 0.0 5.50*
35.0 0.0 5.7*
50.0 6.0 4.15*
55.0 27.0 6.45*
60.0 55.0 6.95*
aData from Experiment 1, all other data is from Experiment 2.
*Statistically significant P < 0.05.
Table 5. In vitro micronucleus test of hydrolysed flubendazole
Compound Concentration 
(µg/ml)
Cytotoxicity 
(%)
Frequency of micronucle-
ated binucleate cells (%)
Vehicle – – 0.65
HF 5.0 0% 0.5
HF 20.0 1.0% 0.65
HF 60.0 28.0% 0.50
HF 80.0 38.0.0% 0.95
HF 100.0 54.0% 0.50
Vinblastine 0.06 NM 9.25*
Mitomycin C 0.10 NM 27.8*
NM, not measured; HF, hydrolysed flubendazole.
*Statistically significant P < 0.05.
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aneugenic and clastogenic properties. However, in vitro micronucleus 
tests of flubendazole showed the same high level of aneugenicity in 
the presence and absence of rat liver S9, suggesting that any clasto-
genicity from the reduced metabolite was not detectable under these 
conditions. Both metabolites were, like flubendazole, inactive in the 
Ames test.
In vivo tests of a new oral ASD formulation of flubendazole, 
which provides higher systemic bioavailability than currently 
Figure 3. BMD10 analysis of in vitro MN dose responses in human lymphocytes albendazole (green) flubendazole (black), R-reduced flubendazole (dark blue), 
S-reduced flubendazole (light blue) and albendazole sulfoxide (red), in human lymphocytes. The top figure shows that the four parameter (m5-bv) exponential 
model provided a suitable fit to each dose response using the compound as covariate for BMD analysis. The dotted lines show the BMD10 derivations for each dose 
response, and these correspond to the mid-point for each line plotted in the bottom figure. These lines in the bottom graph span the BMDL10 to the BMDU10 derived 
from the top figure using PROAST v50.8. Albendazole and flubendazole were equipotent, and the R- and S-metabolites of flubendazole were less potent and of 
similar potency to albendazole sulfoxide. Hydrolysed flubendazole showed no dose response using BMD analysis and was omitted from this covariate analysis.
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marketed formulations, show that this compound is also a potent 
aneugen in vivo, as shown by the results of a bone marrow micro-
nucleus test in the rat. The previous bone marrow micronucleus test 
of flubendazole, using the marketed oral GI formulation that results 
in little systemic availability, was negative. The results in this arti-
cle show the dramatic difference changes in formulation can make 
to a compound’s toxicity profile, if it provides for greater systemic 
exposure. This has previously been demonstrated with flubendazole 
in developmental toxicity tests (38).
Flubendazole has been in use for many years as an anti-helmintic 
treatment for GI parasitic infections, both for humans and various 
animal species (6). The usual dosage of flubendazole in humans for 
this indication is 100 mg once or twice a day for 3 days with systemic 
exposures resulting in plasma Cmax ‘s of <1 ng/ml, although higher 
exposures have been noted if the compound is given with food. Thus, 
using the original commercial oral GI formulation, this compound 
is poorly bioavailable. Although toxic to GI-located parasites, there 
is little reported local GI or systemic toxicity in patients or in the 
animal species used in toxicology testing. The original genotoxicity 
tests of flubendazole provided for pharmaceutical registration of this 
indication showed a lack of mutagenicity in the Ames test and also 
a lack of clastogenicty or aneugenicity in vivo in the mouse bone 
marrow test.
It is known that flubendazole can bind to tubulin at the colchi-
cine binding site, interfering with tubulin polymerisation, disrupting 
microtubule formation and interfering with normal mitosis. Due to 
the close chemical similarity with other aneugenic benzimidazoles, 
such as albendazole and mebendazole (flubendazole is a fluoro ana-
logue of mebendazole), the aneugenic activity of flubendazole is not 
a surprise. The UK Committee on Mutagens has considered that the 
available data for these compounds can be regarded as belonging to 
a common mechanistic group with a similar MOA (20). As the target 
Table 8. In vitro tests of comparator benzimidazoles
Compound Concentration (µg/ml) Cytotoxicity (%) Frequency of micronucleated binucleate cells (%)
Albendazole 0.00 0.0 0.45
0.04 11.0 0.45
0.16 18.0 1.20*
0.70 32.0 4.20*
3.00 12.0 4.00*
Albendazole sulfoxide 0.0 0.0 0.60
3.0 1.0 0.30
10.0 3.0 1.85*
30.0 23.0 3.70*
40.0 20.0 5.50*
Flubendazole 0.000 0.0 0.40
0.025 4.0 0.20
0.100 2.0 0.40
0.400 6.0 4.75*
2.00 24.0 5.30*
*Statistically significant P < 0.05.
Table 9. Mechanistic study to determine the nature (aneugenic vs. clastogenic) of the micronuclei from the in vitro micronucleus test of the 
reduced flubendazole enantiomers (R and S)
Compound Concentration 
(µg/ml)
Fold increases in MN over 
concurrent vehicle control
%C+ micronuclei %C− micronuclei Total MN cells scored
R-reduced flubendazole (RRF) 3.2 7.5 40 60 100
RRF 8.8 9.2 57 43 82
RRF 24.5 14.7 49 51 57
S-reduced flubendazole (SRF) 4.2 2.2 39 61 100
SRF 11.7 6.7 33 67 100
SRF 32.4 9.5 37 63 67
Albendazole 0.7 9.3 72 28 100
Albendazole sulfoxide 30.0 6.2 71 29 100
Flubendazole 2.0 7.1 70 30 100
Mitomycin C 0.1 35 7 93 100
Table 10. Data on flubendazole exposure from a previous single 
dose rat study
Dose (mg/kg) Cmax (µg/ml) AUC 0–24 (µg·h/ml)
65.0 0.91 15.10
130.0 0.90 16.48
402.0 1.33 24.92
Table 11. In vivo rat micronucleus test
Dose (mg/kg) % Micronucleated PCE % PCE
0 0.21 45.83
65.0 1.35* 31.74
130.0 2.31* 33.00
400.0 1.94*
*Statistically significant.
318 D. J. Tweats et al., 2016, Vol. 31, No. 3
D
ow
nloaded from
 https://academ
ic.oup.com
/m
utage/article-abstract/31/3/309/2622793 by Sw
ansea U
niversity user on 14 August 2019
for all three compounds is a protein, rather than DNA, it is accepted 
that such compounds have a threshold below which no aneugenicity is 
induced (13,14). Using various analytical functions to determine PoDs 
in vitro and in vivo and making comparisons with related compounds 
from literature sources, it has been shown in this article that flubenda-
zole, albendazole and mebendazole share similar PoD values for aneu-
genicity derived from in vitro micronucleus tests. This correlation for 
all of these antihelmintics was also clearly shown in the recent study 
in Chinese hamster CHO-K1 cells, where oxibendazole also showed a 
closely linked PoD for MNBN, but where thiabendazole was inactive, 
as shown in Table 4 [derived from reference (19)].
With regard to the metabolites of flubendazole, the hydrolysed 
form was inactive in in vitro micronucleus tests. The two enanti-
omers of the reduced metabolite (R, S) were equipotent with alben-
dazole sulfoxide, and all were significantly less potent that their 
respective parent compounds.
In terms of PoD metrics for micronucleus induction in vivo 
after oral dosing with the new ASD formulation of flubendazole, 
the BMDL1SD metric from the rat in vivo study was used to derive 
a reference dose (RfD) (32,34) of 14.06 mg/subject/day (Figure 4). 
However, it could be argued that using this metric in place of the 
NOGEL or BMD1SD could reduce the need for an uncertainty factor 
of 10 (as included in the original calculation), resulting in a revised 
RfD of 140.62 mg/subject/day (33).
Analysis of plasma samples from rats dosed orally with fluben-
dazole using the new ASD formulation from the in vivo micro-
nucleus test have shown that the principal metabolite is the 
hydrolysed form (Table 4). The reduced metabolite is only found 
at 100 ng/ml after dosing with 400 mg/kg of flubendazole. Thus, if 
patients show a similar profile of metabolite formation to the rat, 
it is likely that plasma exposure to the reduced metabolite will be 
very low, although it would be helpful for risk assessment purposes 
to determine if it is likely that this metabolite could accumulate in 
specific tissues.
Flubendazole has been tested for carcinogenicity in both rats and 
mice using formulated diet at doses equivalent to a maximum of 20 mg/
kg in rats and 30 mg/kg in mice. Neither showed evidence of carcino-
genicity in any tissue including the GI tract (8). Although systemic 
exposure data were not reported in these tests, separate studies in the 
Wistar rat, after an oral dose of 40 mg/kg, using a microsuspension 
of flubendazole, showed that after 4 h, plasma levels of flubendazole 
reached 81 ng/ml. In a separate study in the same strain given 10 mg/kg 
of a microcrystalline suspension of 14C-labelled flubendazole, plasma 
levels reached 0.27µg/ml. The amount of total radioactivity present in 
the liver, lung, kidney, muscle and fat did not exceed 3.1 µg/g of tissue 
(39). It should be noted that the level observed in plasma after dosing 
with 10 mg/kg of flubendazole is similar to the POD metrics for ane-
uploidy calculated for this compound in in vitro tests.
Analysis of faeces after oral dosing with flubendazole shows that 
the vast majority of the administered dose (>85%) is retained in the 
GI tract and appears in the faeces as the unchanged parent molecule 
(40). Thus, these studies do not provided definitive evidence of a lack 
of carcinogenicity in organs exposed via the systemic circulation at 
higher exposures of flubendazole and its metabolites such as those 
obtained after oral doses of flubendazole using formulations such as 
that described in this article.
Albendazole and mebendazole have been tested for carcinogenic-
ity in lifetime studies in the rat and mouse (41–43). Both compounds 
were deemed negative for carcinogenicity in both test species. In the 
case of mebendazole carcinogenicity studies, there have been some 
Figure 4. In vivo MN dose responses from the rat study outlined in Table 4. BMDS was used to defined BMD1SD metrics, and log transformed response data 
provided a normal distribution and homogeneous variance as measured through the Shapiro–Wilks and Bartlett’s test, respectively, so were used for the 
analysis (35). The polynomial model was the most suitable for these data. A BMD1SD, 18.9699 and BMDL1SD, 14.6483 were derived from this model. A reference 
dose (RfD) calculated using this value would be calculated a scaling factor of 0.16 for rat to human, 60 kg person, and an uncertainty factor of 10 for unknown 
differences; [(14.6483 × 0.16 × 60)/10] × 1000 = 14.06 mg/person/day. Note that if the uncertainty is taken into account by use of the lower bound of the BMD1SD 
(BMDL1SD) compared with the BMD1SD or the NOGEL, then this factor of 10 is removed and you obtain a reference dose = 140.62 mg/person/day.
Table  12. Exposure data including metabolites from the in vivo  
micronucleus test
Compound Mean plasma concentration, ng/ml  
(9 ha after dose of 400 mg/kg)
Flubendazole 610
Reduced flubendazole 105
Hydrolysed flubendazole 20 400
aNine hours represents the approximate Tmax from a previous pharmaco-
kinetic experiment.
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criticisms of the study design due to poor survival and less than opti-
mal histology. However, these data have been regarded as sufficient 
to define non-carcinogenicity by regulatory authorities. For the car-
cinogenicity studies of albendazole, an assessment by a joint FAO/
WHO Expert committee on Food Additives noted that questions 
had been raised regarding the statistical analysis of the data from 
the rat and mouse carcinogenicity studies and the use of historical 
controls in the examination of the incidence of tumours. Thus, these 
studies were reviewed and were deemed to be satisfactory (41). Thus, 
these studies have passed scrutiny by many regulatory authorities 
around the world, including those in the USA, sufficient to allow 
their unrestricted use, including mass administration in the case of 
albendazole. Thus, although both compounds are aneugenic, this 
does not predict their lack of carcinogenicity under the conditions of 
the rodent tests provided. Both compounds are in widespread human 
use as anti-parasitic therapies. Albendazole is of particular interest as 
it is used in MDA programmes to control filariasis, involving almost 
a billion patients to date, who have been dosed with the compound 
in a small number of doses annually, but repeated over many years 
of treatment.
The proposed therapeutic use of flubendazole will be for the 
administration of a low number of doses to affected patients. A for-
mulation that can achieve higher systemic exposure, such as used in 
this article, will have the potential to kill macrofilaria resulting also 
in loss of microfilaria, without the need for repeated dosing with 
similar compounds (such as albendazole) over more than a decade, 
as is currently the case. In addition it has the potential to avoid the 
encephalopathy and brain dysfunction seen in patients co-infected 
with Onchocerca and L. loa and treated using ivermectin alone or 
in combination with albendazole. Whether the chosen dose will 
produce an exposure of flubendazole that exceed the threshold for 
aneugenicity, is unknown. In addition, there will be exposure in 
patients to low levels of the R-reduced metabolites, which have 
shown both clastogenic and aneugenic potential when tested in 
isolation in vitro. However, taking into account the minimal dura-
tion of the intended dosing period and the lack of carcinogenic-
ity of closely related compounds with the same aneugenic MOA 
this therapy is unlikely to pose a carcinogenic risk to patients. 
Mebendazole is also used in single doses (e.g. Vermox® at 500 mg) 
for particular parasitic infections also resulting in exposures that 
most likely exceed the aneugenic threshold (human PK studies have 
shown that at high therapeutic doses, oral bioavailability is around 
2%) (44).
In summary, this article shows that flubendazole is a potent aneu-
gen, in vitro and in vivo. The latter contrasts with previously negative 
findings in vivo where the formulation did not provided significant 
systemic exposure. New approaches have been used to establish PoD 
metrics for flubendazole and its metabolites, which will be useful 
when therapeutic doses of flubendazole are established for treating 
serious cases of co-infection with specific filarial parasites.
Supplementary data
Supplementary Method, Tables 1a and 1b and Figures 1 and 2 are 
available at Mutagenesis Online.
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